
Opinion|Videos|March 13, 2025
Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies
Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.
Advertisement
Video content above has been prompted by the following:
- How do patient characteristics (eg, brain metastases, other comorbidities, prior therapies) influence ADC therapy selection?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5